BS_KE56MMY0
Neurofibroma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Neurofibroma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Neurofibroma
- overall_survival_months
- 19.316688567674113
- age_years
- 17.392
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.503
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.486
- G2M_CHECKPOINT+0.469
- MYC_TARGETS_V2+0.459
- E2F_TARGETS+0.456
- IL6_JAK_STAT3_SIGNALING+0.413
- TNFA_SIGNALING_VIA_NFKB+0.402
- ALLOGRAFT_REJECTION+0.390
- INTERFERON_GAMMA_RESPONSE+0.385
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.365
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.376
- KRAS_SIGNALING_DN-0.294
- BILE_ACID_METABOLISM-0.220
- MYOGENESIS-0.197
- PANCREAS_BETA_CELLS-0.184
- SPERMATOGENESIS-0.109
- ESTROGEN_RESPONSE_LATE-0.071
- XENOBIOTIC_METABOLISM-0.069
- HEME_METABOLISM-0.050
- UV_RESPONSE_UP-0.045
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | F873381B-3D15-47B2-9385-080590B316B7 | — | — | 0.957 |
| 2 | SRR934932 | — | — | 0.952 |
| 3 | 8B4E465B-0FD5-4154-824B-1E6B2656FD2F | — | — | 0.951 |
| 4 | SRR934839 | — | — | 0.948 |
| 5 | SRR934837 | — | — | 0.946 |
| 6 | SRR934958 | — | — | 0.940 |
| 7 | SRR934730 | — | — | 0.939 |
| 8 | SRR934925 | — | — | 0.931 |
| 9 | SRR934965 | — | — | 0.931 |
| 10 | 65F93AB7-AA99-49B5-8D59-7D0DE9CA9E34 | — | — | 0.931 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.503 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.486 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.469 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.459 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.456 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.413 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.402 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.390 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.385 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.365 | Inavolisib | — uncovered |
| APOPTOSIS | 0.352 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.352 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.351 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.346 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.334 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.329 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.328 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.324 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.311 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.307 | Remibrutinib | — uncovered |